Last reviewed · How we verify
Rhinoptil (CAFAMINOL)
Rhinoptil (generic name: CAFAMINOL) is a drug. It is currently in Phase 2 development.
Rhinoptil (CAFAMINOL) is a small molecule that works by interacting with a specific biological target to produce a therapeutic effect.
Rhinoptil (CAFAMINOL) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. There is limited information available on its approved indications, half-life, and bioavailability. Further research is needed to understand its mechanism of action and key safety considerations. As a result, it is difficult to provide a comprehensive summary of this drug.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | CAFAMINOL |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine Rhinoptil (CAFAMINOL) as a key that fits into a lock on a cell. When it binds to the lock, it triggers a series of events that ultimately lead to the desired therapeutic effect. This process is highly specific and allows the drug to target only certain cells or pathways, minimizing side effects.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rhinoptil CI brief — competitive landscape report
- Rhinoptil updates RSS · CI watch RSS
Frequently asked questions about Rhinoptil
What is Rhinoptil?
How does Rhinoptil work?
What is the generic name of Rhinoptil?
What development phase is Rhinoptil in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing